REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...

REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx 1 and PlanB 2 studies, the 16 th St. Gallen International Breast ...

- Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test's impact on clinical practice with ...

A brief summarizing significant news from this year's San Antonio Breast Cancer Symposium regarding the TransATAC study's results showing that Oncotype DX may now be available for use in women who ...

The Ontario DCIS Study Group in Canada conducted this clinical study which met its primary endpoint by substantiating that the Oncotype DX DCIS Score can predict the risk of local recurrence. Local ...

Genomic-based clinical laboratory service provider Genomic Health Inc. (GHDX) reported results from two studies that evaluated the company's Oncotype DX test in personalizing prostate cancer treatment ...

MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast ...

In the new era of personalized medicine, having more information on hand is considered the ideal situation for making more customized, and ideally, effective decisions about medical care. And in a new ...

PHILADELPHIA (WPVI) -- Year by year, treatment for breast cancer is evolving, becoming more effective and more individualized. There was a time when breast cancer treatment was based mostly on tumor ...

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million (about 2 percent of the overall costs in the ...

A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS. A part of precision medicine involves ...

As FOXA1, GATA3, and ER coexist in a network regulating luminal subtype A breast carcinomas, we hypothesized that tumors expressing FOXA1 and/or GATA3 will have a low recurrence score. We therefore ...